The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/22984

Please be advised that this information was generated on 2019-04-02 and may be subject to change.
Anti-Pfs25 monoclonal antibody 32F81 blocks transmission from *Plasmodium falciparum* gametocyte carriers in Cameroon

Bert Mulder, Will Roeffen, Robert Sauerwein, Timoléon Tchuinkam, Christian Boudin and Jan Peter Verhave

**Keywords:** malaria, *Plasmodium falciparum*, transmission-blocking antibody

Pfs25 is a target protein for the induction of antibodies that block transmission of *Plasmodium falciparum*. Anti-Pfs25 monoclonal antibody (mAb) 32F81 has been generated against gametes of strain NF54 and shown to block the oocyst development in mosquitoes fed on red blood cell suspensions containing NF54 gametocytes (Vermeulen *et al.*, 1985). Comparison of the genes encoding Pfs25 in 8 isolates of different geographical origin showed almost complete sequence homology (Kaslow *et al.*, 1989). Since transmission blocking activity of 32F81 has been reported for NF54 only, we wanted to test the capacity of this mAb to block transmission of field isolates by experimentally feeding local *Anopheles gambiae* on blood from naturally infected carriers of *P. falciparum* gametocytes. mAb 32F81 was added to the blood meal at a concentration of 50 μg/mL. A blood meal from the same gametocyte carrier without the mAb was used as a control. Gametocyte density was estimated from the parasite/leucocyte ratio by counting gametocytes against 1000 white blood cells and assuming an average leucocyte count of 8000/μL. In 5 mosquitoes, fed on persons with >200 gametocytes per μL, round forms (activated macrogametocytes) and zygotes were searched for 4 h after the blood meal, using mAb 32F81 labelled with fluorescein isothiocyanate. Ookinete numbers were also looked for in 5 mosquitoes 24 h after the blood meal. After 7 d, surviving mosquitoes were dissected for the presence and number of oocysts. Thirty-three infection experiments were performed and 2292 mosquitoes were dissected. The mean age of the gametocyte carriers was 20-3 years (range 4-44 years) and the mean gametocyte density was 232/mm³. Mean numbers (per mm³) of round forms (10±4±9+6) and ookinetes (0±6±1±3) were lower in the 32F81 group, but not significantly so, than in the control group (18±7±26±7 and 9±0±21, respectively). Blood meals from 13 gametocyte carriers gave rise to oocysts (Table). Their mean age was 18-5 years and their mean gametocyte density was 400/mm³. In the experimental group 430 mosquitoes were dissected, and in the control group 498. The mean percentage of oocyst-infected mosquitoes in the control group was 35, while in those fed on blood containing mAb 32F81 it was 175 (1±0±002, Mann-Whitney U test). While the mean oocyst number in the control group was over 7, the 32F81 experimental group yielded a mean of less than one oocyst per mosquito (P<0.003, Mann-Whitney U test). The 3 subjects with the highest gametocyte numbers showed significantly higher infection percentages even in the 32F81 group (P<0.05 Mann-Whitney U test).

We conclude that mAb 32F81 can block transmission from naturally infected *P. falciparum* gametocyte carriers to a local strain of *A. gambiae*, as has been shown by Vermeulen *et al.* (1985) and Mulder *et al.* (1994) for a laboratory-adapted strain of *P. falciparum*. These findings are in agreement with the almost complete genetic homology of Pfs25 in different isolates, which has been considered to support the development of a transmission-blocking vaccine based on this protein. Transmission blocking is more effective at low gametocyte densities, which are prevalent under natural conditions, and this confirms previous findings in experimental infections (Ponnudurai *et al.*, 1987). In addition to naturally occurring transmission-blocking vaccine candidate of *P. falciparum* in endemic countries (Mulder *et al.*, 1994), immunization using a Pfs25 vaccine might further reduce malaria transmission (Kaslow *et al.*, 1991; Kaslow, 1993).

**Acknowledgements**

We thank the staff and patients of the Messa dispensary, Yaoundé, for their co-operation, Julienne Essong and Mariene Sieben for technical assistance, and Isabella Quakyi for critically reading the manuscript. Written permission for blood taking was given to OCEAC by the Cameroonian Ministry of Public Health.

**References**


